1997 Constitution of Fiji: Chapter 3

Superdry plc: ROI-Result of Equity Issue

Retrieved on: 
Thursday, May 4, 2023
MAKE, 10A, Financial Conduct Authority, Person, II, LONDON, UNITED STATES, NO, 1997 Constitution of Fiji: Chapter 3, Investment, European Economic Area, Risk, Prejudice, Markets in Financial Instruments Directive 2014, Financial Services and Markets Act 2000, London Stock Exchange, FSMA, Relevance (Person of Interest), Trustee, SELL, Uncertainty, European Union (Withdrawal) Act 2018, ALL, Disclosure, Main Market, Onitsha, Finance, US, FCA, FORM, Fiscal policy, AFRICA, Financial services, Reproduction, Sale, Republic, Prospectus, London, Nature, ANY, AN, United Kingdom, Security (finance), Cryptocurrency, Liberum veto, Superdry, EU, Regulation

The distribution of this Announcement and the Equity Raise and/or the offer or sale of the New Ordinary Shares in certain jurisdictions may be restricted by law.

Key Points: 
  • The distribution of this Announcement and the Equity Raise and/or the offer or sale of the New Ordinary Shares in certain jurisdictions may be restricted by law.
  • This Announcement does not constitute a recommendation concerning any investor's options with respect to the Equity Raise.
  • The UK Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Equity Raise.
  • The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Equity Raise.

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

Retrieved on: 
Tuesday, March 14, 2023
European Union (Withdrawal) Act 2018, EEA, Person, Financial services, Prejudice, Markets in Financial Instruments Directive 2014, Finance, HarbourVest Global Private Equity, FCA, 1997 Constitution of Fiji: Chapter 3, Investment, Financial Services and Markets Act 2000, FSMA, Subscription business model, Disclaimer, EU

LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease ("DED") to address the significant unmet need in this multi-billion-dollar market, is pleased to announce a "reasonable best efforts" offering of its American Depositary Shares ("ADSs") on the Nasdaq Capital Market (the "U.S. Offering") and a subscription for new ordinary shares of no par value (the "Ordinary Shares") (the "Subscription" and, together with the U.S. Offering, the "Global Private Placement").

Key Points: 
  • There will be no offer of New ADSs or Subscription Shares to the public in any EEA member state.
  • There will be no offer of New ADSs or Subscription Shares to the public in the UK.
  • The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Global Private Placement.
  • Each distributor is responsible for undertaking its own target market assessment in respect of the New ADSs and/or the Subscription Shares and determining appropriate distribution channels.

Millicom announces the terms of its rights offering

Retrieved on: 
Wednesday, May 18, 2022
Rights, Tower, Morgan Stanley, Financial Services and Markets Act 2000, Financial Conduct Authority, COBS, Pandemic, Directive 2014/65/EU, Securities Act of 1933, 1997 Constitution of Fiji: Chapter 3, Face, SEC, II, Investment, Acceleration, Rump, COVID-19, Failure, United Kingdom, Joint, Growth, Financial services, Prospectus, European Economic Area, EDGAR, Telecommunication, European Union (Withdrawal) Act 2018, Communication, Security (finance), Share repurchase, Goldman Sachs, PRA, Prejudice, 10A, Industry, Finance, Technology, Sale, J.P. Morgan & Co., Person, Property management, Public relations, Risk management, Renewable energy, Retail, Bank, Millicom, EU, Swedish

The contents of this press release have been prepared by and are the sole responsibility of Millicom.

Key Points: 
  • The contents of this press release have been prepared by and are the sole responsibility of Millicom.
  • The Joint Bookrunners are acting exclusively for Millicom and no-one else in connection with the Rights Offering, and will not regard any other person as their respective clients in relation to the Rights Offering and will not be responsible to anyone other than Millicom for providing the protections afforded to their respective clients nor for providing advice in relation to the Rights Offering or any other matters referred to in this press release.
  • Millicom has filed a registration statement (including a prospectus) with the SEC on March 1, 2022 covering, among other things, the rights offering to which this communication relates.
  • The Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Rights Offering.

Result of Placing

Retrieved on: 
Monday, December 20, 2021
ACT, Place, UNITED KINGDOM, NO, FINANCIAL, AFRICA, Risk, IT, London Stock Exchange, London Stock Exchange Group, SALE, Legislation, ALL, Person, Honda UK Manufacturing, PART, Forward-looking statement, FCA, AND, Uncertainty, Financial Conduct Authority, ETC, WITH, Nature, THE, EUROPEAN UNION, Prejudice, Disclaimer, AS, NET, EEA, Official List, INTO, 1997 Constitution of Fiji: Chapter 3, Handbook, OR, II, Company, European Economic Area, Paragraph, 10A, Exercise, Directive 2014/65/EU, Income, ARE, ANY, Goal, Trustee, Better Place (company), WHO, Dowgate, Security (finance), Cryptocurrency, Life insurance, Distribution (marketing), EU

NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN THE UNITED STATES OR ELSEWHERE.

Key Points: 
  • NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN THE UNITED STATES OR ELSEWHERE.
  • The distribution of this Announcement and/or the Placing and/or issue of the Placing Shares in certain jurisdictions may be restricted by law.
  • The Placing Shares to be issued pursuant to the Placing will not be admitted to any stock exchange other than the standard segment of the Official List and to trading on the London Stock Exchange's Main Market.
  • Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares determining appropriate distribution channels.

Brigade-M3 European Acquisition Corp. End of Stabilisation

Retrieved on: 
Friday, December 17, 2021
Professional Services, Finance, European Union (Withdrawal) Act 2018, Risk, Financial services, FSMA, Legislation, Person, Prospectus, Forward-looking statement, FCA, Confidentiality, Financial Services and Markets Act 2000, United Kingdom, Prejudice, Disclaimer, Common stock, Admission, EEA, Business architecture, Euronext Amsterdam, 1997 Constitution of Fiji: Chapter 3, Offering, Investment, MIFID, II, Mission statement, European Economic Area, Company, Business, Sale, Directive 2014/65/EU, Trustee, Finance, Security (finance), Medical device, Risk management, Financial adviser, Unit, COBS, EU, Warrant, Regulation

In the EEA, this announcement is only directed at persons who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended.

Key Points: 
  • In the EEA, this announcement is only directed at persons who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended.
  • This announcement must not be acted on or relied on by persons in the United Kingdom who are not relevant persons.
  • Any purchase of any securities in the Offering should be made solely on the basis of information contained in the Prospectus.
  • No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

EQS-News: CHRONEXT AG: CHRONEXT AG postpones contemplated IPO

Retrieved on: 
Wednesday, October 6, 2021
Publication, European Economic Area, Securities Act of 1933, 10A, Advertising, UBS AG, II, 1997 Constitution of Fiji: Chapter 3, Person, Intention, Prejudice, FSMA, Investor relations, Financial services, Post office box, Urban economics, European Union (Withdrawal) Act 2018, Disclaimer, United Kingdom, UBS, European Union, Finance, Financial Services and Markets Act 2000, EEA, Directive 2014/65/EU, District, Prospectus, Security (finance), Life insurance

A decision to invest in securities of CHRONEXT AG should be based exclusively on the prospectus published by CHRONEXT AG (the "Company") for such purpose.

Key Points: 
  • A decision to invest in securities of CHRONEXT AG should be based exclusively on the prospectus published by CHRONEXT AG (the "Company") for such purpose.
  • Copies of such prospectus (and any supplements thereto) are available free of charge from UBS AG, Swiss Prospectus Switzerland, P.O.
  • CHRONEXT AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
  • Except as required by applicable law, CHRONEXT AG has no intention or obligation to update, keep updated or revise this publication or any parts thereof following the date hereof.

EQS-News: CHRONEXT AG: sets price range at CHF 16 to CHF 21 per share

Retrieved on: 
Tuesday, September 28, 2021
Securities Act of 1933, 1997 Constitution of Fiji: Chapter 3, Person, FSMA, District, United Kingdom, Prejudice, Investor relations, Finance, Directive 2014/65/EU, Prospectus, European Economic Area, UBS AG, Financial services, Post office box, Urban economics, Disclaimer, EEA, Financial Services and Markets Act 2000, Publication, 10A, Advertising, II, Intention, European Union (Withdrawal) Act 2018, UBS, European Union, Security (finance), Life insurance

Any investment decisions with respect to any securities should not be made based on this advertisement.

Key Points: 
  • Any investment decisions with respect to any securities should not be made based on this advertisement.
  • A decision to invest in securities of CHRONEXT AG should be based exclusively on the prospectus published by CHRONEXT AG (the "Company") for such purpose.
  • Copies of such prospectus (and any supplements thereto) are available free of charge from UBS AG, Swiss Prospectus Switzerland, P.O.
  • CHRONEXT AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.